Skip to main content
Livermore
Livermore
ZHEN

Brainstorm Cell Therapeutics Inc.

BCLI
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001137883

No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

13F holders, Q4 2021

Institutional positions in Brainstorm Cell Therapeutics Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
42
−9 vs. Q3 2021
Shares held
4.40M
−714.9K (−14.0%) vs. Q3 2021
Total value
$17.6M
+$715.0K (+4.2%) vs. Q3 2021
New holders
6
8 more added
Sold out
15
12 more reduced

1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting BCLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2021: 42 institutions
Q1 2021: 75 institutionsQ2 2021: 57 institutionsQ3 2021: 52 institutionsQ4 2021: 42 institutionsQ1 2022: 39 institutionsQ2 2022: 48 institutionsQ3 2022: 42 institutionsQ4 2022: 43 institutionsQ1 2023: 48 institutionsQ2 2023: 57 institutionsQ3 2023: 53 institutionsQ4 2023: 46 institutionsQ1 2024: 47 institutionsQ2 2024: 48 institutionsQ3 2024: 38 institutionsQ4 2024: 34 institutionsQ1 2025: 32 institutionsQ2 2025: 34 institutionsQ3 2025: 5 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ4 2021: $17.6M
Q1 2021: $32.1MQ2 2021: $21.4MQ3 2021: $16.9MQ4 2021: $17.6MQ1 2022: $14.0MQ2 2022: $11.0MQ3 2022: $17.1MQ4 2022: $6.16MQ1 2023: $20.4MQ2 2023: $11.5MQ3 2023: $928.4KQ4 2023: $1.04MQ1 2024: $2.19MQ2 2024: $4.09MQ3 2024: $2.52MQ4 2024: $560.3KQ1 2025: $1.09MQ2 2025: $264.0KQ3 2025: $1.73KQ4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding BCLI and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20255$1.73K
Q2 202534$264.0K
Q1 202532$1.09M
Q4 202434$560.3K
Q3 202438$2.52M
Q2 202448$4.09M
Q1 202447$2.19M
Q4 202346$1.04M
Q3 202353$928.4K
Q2 202357$11.5M
Q1 202348$20.4M
Q4 202243$6.16M
Q3 202242$17.1M
Q2 202248$11.0M
Q1 202239$14.0M
Q4 202142$17.6M
Q3 202152$16.9M
Q2 202157$21.4M
Q1 202175$32.1M

Institutions, Q4 2021

Shares, value and share of portfolio for each institution holding Brainstorm Cell Therapeutics Inc.; share changes are against Q3 2021.

Institutions holding BCLI in Q4 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc1,430,572$5.72M0.00%−1,847−0.1%Reduced
Sabby Management, LLC513,211$2.05M0.51%+36,886+7.7%Added
BlackRock Inc.472,476$1.89M0.00%+3,509+0.7%Added
Ikarian Capital, LLC289,550$1.16M0.33%00.0%Unchanged
Geode Capital Management, LLC278,101$1.11M0.00%+2,351+0.9%Added
Abner Herrman & Brock LLC233,000$932.0K0.12%+28,000+13.7%Added
JPMorgan Chase & Co193,166$773.0K0.00%−252,532−56.7%Reduced
Raymond James & Associates189,503$758.0K0.00%−10,265−5.1%Reduced
Weaver Consulting Group155,500$622.0K0.30%+104,000+201.9%Added
Millennium Management LLC150,166$601.0K0.00%−161−0.1%Reduced
Price T Rowe Associates Inc93,000$372.0K0.00%00.0%Unchanged
State Street Corp86,703$347.0K0.00%00.0%Unchanged
Northern Trust Corp59,091$236.0K0.00%00.0%Unchanged
Morgan Stanley51,660$207.0K0.00%−854−1.6%Reduced
Boothbay Fund Management, LLC29,186$117.0K0.00%00.0%Unchanged
Wells Fargo & Company18,558$74.0K0.00%+5,376+40.8%Added
UBS Group AG14,407$58.0K0.00%+3,399+30.9%Added
S.C. Financial Services, Inc.15,285$52.0K0.06%+15,285New
Aptus Capital Advisors, LLC12,500$50.0K0.00%−3,500−21.9%Reduced
Bank of New York Mellon Corp12,250$49.0K0.00%−3,649−23.0%Reduced
Raymond James Financial Services Advisors, Inc.12,031$48.0K0.00%−700−5.5%Reduced
CFO4Life Group, LLC12,000$48.0K0.01%00.0%Unchanged
Charles Schwab Investment Management Inc11,287$46.0K0.00%00.0%Unchanged
Two Sigma Advisers, LP11,600$46.0K0.00%+900+8.4%Added
Advisor Group Holdings, Inc.10,120$40.0K0.00%−800−7.3%Reduced
Geneos Wealth Management Inc.10,100$40.0K0.00%+10,100New
Steward Partners Investment Advisory, LLC9,700$39.0K0.00%−7,300−42.9%Reduced
Harbour Investments, Inc.4,399$18.0K0.00%−3,870−46.8%Reduced
Bank Julius Baer & Co. Ltd, Zurich4,167$17.0K0.00%00.0%Unchanged
Tower Research Capital LLC (TRC)3,442$14.0K0.00%+3,442New
Bank of America Corp3,092$12.0K0.00%−8,635−73.6%Reduced
Institutional & Family Asset Management, LLC3,000$12.0K0.00%00.0%Unchanged
Washington Trust Co2,500$10.0K0.00%00.0%Unchanged
Royal Bank of Canada1,533$6.00K0.00%00.0%Unchanged
Cypress Capital Management LLC (WY)1,500$6.00K0.01%+1,500New
Aquatic Capital Management LLC800$3.00K0.01%+800New
First Manhattan Co500$2.00K0.00%00.0%Unchanged
BNP Paribas Arbitrage, SA481$1.92K0.00%00.0%Unchanged
CoreCap Advisors, LLC133$1.00K0.00%+133New
Simplex Trading, LLC200$00.00%00.0%Unchanged
Westside Investment Management, Inc.200$00.00%00.0%Unchanged
Mark Sheptoff Financial Planning, LLC100$00.00%00.0%Unchanged
Gsa Capital Partners LLP0$00.00%−172,056−100.0%Sold out
Ergoteles LLC0$00.00%−122,667−100.0%Sold out
Pura Vida Investments, LLC0$00.00%−106,834−100.0%Sold out
HRT Financial LP0$00.00%−81,489−100.0%Sold out
Susquehanna International Group, LLP0$00.00%−39,031−100.0%Sold out
Acadian Asset Management LLC0$00.00%−35,893−100.0%Sold out
Goldman Sachs Group Inc0$00.00%−17,600−100.0%Sold out
Citadel Advisors LLC0$00.00%−16,480−100.0%Sold out
Two Sigma Investments, LP0$00.00%−15,900−100.0%Sold out
Walleye Capital LLC0$00.00%−10,639−100.0%Sold out
Occudo Quantitative Strategies LP0$00.00%−10,168−100.0%Sold out
Barclays PLC0$00.00%−4,267−100.0%Sold out
Deutsche Bank AG0$00.00%−2,100−100.0%Sold out
Brewin Dolphin Ltd0$00.00%−700−100.0%Sold out
FMR LLC0$00.00%−666−100.0%Sold out
HighPoint Advisor Group LLC––––Not filed